Zilovertamab vedotin

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer[1].

Product Specifications

Product Name Alternative

VLS-101; MK-2140

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Apoptosis

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zilovertamab-vedotin.html

Purity

98.61

Solubility

10 mM in DMSO

Smiles

[Zilovertamabvedotin]

Molecular Weight

151000 (average)

References & Citations

[1]Jiang VC, et, al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021 Aug 28;14 (1) :132.